Quan Capital, a healthcare-focused venture capital firm established by the founder of US-listed Chinese drug developer Zai Lab, has closed its second fund with $275 million in commitments.
The vehicle had a target of $250 million, according to industry sources. Its mandate is to incubate and develop next-generation life sciences companies globally as well as in China. There are three main...
Michael Granoff, founder and CEO of Pomona Capital, discusses raising capital from Asian LPs, how GPs can be differentiated in a crowded secondaries market, and why he’s not keen on fund restructurings
Japanese mid-market buyout firm Tokio Marine Capital is spinning out from its corporate parent to form an independent investment manager known as T Capital Partners.
Centurium Capital, CITIC Capital and Hillhouse Capital are part of an investor group targeting a $4.6 billion take-private of China Biologic – just over a year after committing new equity to the US-listed company to protect it from other would-be acquirers.
Groww, an Indian financial technology provider focused on mutual fund investment services, has raised a $21.4 million Series B round led by US-based Ribbit Capital.